Moleculin Biotech
MBRX
8 hedge funds and large institutions have $2.05M invested in Moleculin Biotech in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
0.2% less ownership
Funds ownership: 4.98% → 4.78% (-0.2%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $37K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Securities
New York
|
-$24K |
| 2 |
Centaurus Financial
Anaheim,
California
|
-$13K |
MBRX Hedge Fund Activity: Q3 2018 in Review
8 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2018, worth a combined $2.05M — down 11% from $2.3M a quarter earlier.
Fund positioning in MBRX was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Two Sigma Securities, cutting an estimated $24K.
- 8 institutional investors held Moleculin Biotech (MBRX) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $2.05M of Moleculin Biotech stock for Q3 2018, down 11% quarter-over-quarter.
- 0 funds opened new Moleculin Biotech positions in Q3 2018 and 0 closed out.
- The largest Moleculin Biotech seller in Q3 2018 was Two Sigma Securities, an estimated $24K sold.
Based on aggregated 13F filings for Q3 2018.